Dyne Therapeutics (DYN) Other Non-Current Assets (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Other Non-Current Assets of $11.3 million for Q2 2026, up 350.92% year-over-year from $2.5 million in Q2 2025, and down 27.46% quarter-over-quarter from $15.6 million in Q1 2026.
Dyne Therapeutics (DYN) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Other Non-Current Assets for 8 consecutive years, with $11.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 350.92% year-over-year to $11.3 million; the TTM figure through Jun 2026 stood at $11.3 million (up 350.92% YoY), while the FY2025 annual figure was $15.6 million, up 703.3% from the prior year.
- Other Non-Current Assets retreated to $11.3 million in Q2 2026 per DYN's latest filing, from $15.6 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $15.6 million in Q4 2025 and bottomed at $1.9 million in Q1 2024.
- Historically, Other Non-Current Assets has averaged $4.9 million across 5 years, with a median of $2.3 million in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets declined 19.76% — and 2025, when it jumped 703.3%.
- Dyne Therapeutics' Other Non-Current Assets stood at $2.3 million in 2022, then dropped by 0.17% to $2.3 million in 2023, then declined by 16.11% to $1.9 million in 2024, then surged by 703.3% to $15.6 million in 2025, then dropped by 27.51% to $11.3 million in 2026.
- Business Quant data shows DYN's Other Non-Current Assets at $11.3 million in Q2 2026, $15.6 million in Q1 2026, and $15.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 11.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.31 Mn |
| Mar 31, 2026 | 15.59 Mn |
| Dec 31, 2025 | 15.60 Mn |
| Sep 30, 2025 | 15.01 Mn |
| Jun 30, 2025 | 2.51 Mn |
| Mar 31, 2025 | 1.94 Mn |
| Dec 31, 2024 | 1.94 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 1.92 Mn |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | 2.33 Mn |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | 2.32 Mn |
| Dec 31, 2022 | 2.32 Mn |
| Sep 30, 2022 | 2.32 Mn |
| Jun 30, 2022 | 2.32 Mn |
| Mar 31, 2022 | 2.70 Mn |
| Dec 31, 2021 | 2.70 Mn |
| Sep 30, 2021 | 2.70 Mn |